Swedish Orphan Biovitrum AB (Sobi) today announced that the EU Commission has approved Xiapex (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.  Peyronie's disease is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.

"We are very pleased with the approval by the EU Commission and that we are now able to expand the treatment options for patients with Peyronie's disease. Patients with severe symptoms of their disease, both physical and psychological, can now be offered a therapeutic alternative to surgical intervention," says Birgitte Volck, Senior Vice President & Chief Medical Officer at Sobi.

Xiapex was approved in December 2013 by the Food and Drug Administration (FDA) in the United States for the treatment of Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex (collagenase clostridium histolyticum) is the trade name for Xiapex used in the United States.

For more details, go to: http://www.sobi.com/en/Investors--Media/News/RSS/?RSS=http://cws.huginonline.com/S/134557/PR/201501/1890758.xml